Table 3.
Survival analyses of cancer-specific survival for extremity liposarcoma patients
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| P | HR | 95.0% CI | P | ||
| Age | |||||
| < 65 | Reference | Reference | |||
| 65–76 | 0.416 | 1.25 | 0.83–1.88 | 0.277 | |
| > 76 | < 0.001 | 3.26 | 2.19–4.85 | < 0.001 | |
| Tumor size | |||||
| < 7.4 | Reference | Reference | |||
| 7.4–12.4 | 0.036 | 2.42 | 1.43–4.10 | 0.001 | |
| > 12.4 | < 0.001 | 3.73 | 2.32–6.01 | < 0.001 | |
| Race | |||||
| Black | Reference | ||||
| Other | 0.609 | ||||
| White | 0.668 | ||||
| Sex | |||||
| Female | Reference | Reference | |||
| Male | 0.001 | 1.42 | 1.01–2.00 | 0.047 | |
| Histological type | |||||
| Liposarcoma, NOS | Reference | ||||
| Liposarcoma, well differentiated | < 0.001 | ||||
| Myxoid liposarcoma | 0.668 | ||||
| Round cell liposarcoma | < 0.001 | ||||
| Pleomorphic liposarcoma | < 0.001 | ||||
| Mixed liposarcoma | 0.024 | ||||
| Fibroblastic liposarcoma | 0.966 | ||||
| Dedifferentiated liposarcoma | 0.002 | ||||
| AJCC | |||||
| I/II | Reference | ||||
| III/IV | < 0.001 | ||||
| T | |||||
| T1 | Reference | ||||
| T2 | 0.007 | ||||
| N | |||||
| N0 | Reference | ||||
| N1 | 0.088 | ||||
| M | |||||
| M0 | Reference | Reference | |||
| M1 | < 0.001 | 5.83 | 3.37–10.09 | < 0.001 | |
| Surgery | |||||
| No | Reference | Reference | |||
| Yes | < 0.001 | 0.43 | 0.21–0.85 | 0.015 | |
| Radiotherapy | |||||
| No | Reference | ||||
| Yes | < 0.001 | ||||
| Chemotherapy | |||||
| No | Reference | ||||
| Yes | < 0.001 | ||||
| Primary site | |||||
| Lower extremity | Reference | ||||
| Upper extremity | 0.768 | ||||
| Grade | |||||
| I | Reference | Reference | |||
| II | < 0.001 | 3.95 | 2.13–7.33 | < 0.001 | |
| III | < 0.001 | 14.10 | 8.34–23.85 | < 0.001 | |
| IV | < 0.001 | 19.02 | 11.41–31.71 | < 0.001 | |
HR Hazard ratio, CI Confidence interval, AJCC American Joint Committee on Cancer